Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pradefovir Mesylate vs Other Nucleos(t)ide Analogues in Chronic Hepatitis B with High Baseline HBsAg
ChiCTR2500112207Phase 4Recruiting
- Sponsor
- Xixi Hospital of Hangzhou
- Start
- Nov 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of pradefovir in Chronic Hepatitis B (CHB) (2 arms), sponsored by Xixi Hospital of Hangzhou. Primary endpoint: Proportion of clinical cure-favorable population at Week 48. Started Nov 2025; status: recruiting.
02
Drugs
pradefovir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2500112207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112207.